NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio ® (avelumab), a ...
Abstract 7901: Renal cancer early diagnosis using a novel B7-H3 targeted ultrasound contrast imaging
AbstractAim:. Cost-effective or accessible methods to detect kidney cancers, especially those with renal insufficiency, remain elusive. We propose ultrasound molecular imaging (UMI) using microbubbles ...
Cancer Res (2024) 84 (17_Supplement_2): A029. The success of large language models (LLMs) with attention mechanisms in natural language processing has inspired a series of LLMs for single-cell ...
Abstract. Activating mutations in KRAS drive pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Although mutant-selective KRAS inhibitors and pan-RAS inhibitors provide ...
Abstract. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a five-yearsurvival below 12%. This poor prognosis stems from the ...
JNJ-95437446 is a potential best-in-class EGFR/MET bispecific antibody drug conjugate designed to deliver a cytotoxic payload to tumor cells while leveraging the unique characteristics of amivantamab.
In DESTINY-Breast01 (NCT03248492) and DESTINY-Breast03 (NCT03529110), trastuzumab deruxtecan (T-DXd) demonstrated unprecedented activity in patients (pts) with HER2+ (immunohistochemistry 3+; ...
This section provides detailed general style and formatting requirements for manuscripts published in the AACR journals. For initial submission, the AACR journals do not impose strict article size or ...
From molecules to medicine, from proteomics to prevention, the journals of the AACR cover the entire spectrum of cancer research. Please select the journal that is most appropriate for your manuscript ...
Ming Li Han Liang Jonathan Licht De-Chen Lin Hui-Kuan Lin Piro Lito David Lyden Conor C. Lynch Mathieu Lupien Li Ma Anant Madabhushi Andriy Marusyk Massimiliano Mazzone John D. Minna Lindsay M. Morton ...
Abstract. Advances in cancer prevention, early detection, and treatment have led to substantial improvements in cancer outcomes in the United States over the past several decades. Despite this ...
Background: Zelenectide pevedotin (zele, formerly BT8009) is a highly selective Bicycle® Toxin Conjugate (BTC) comprised of a bicyclic peptide targeting Nectin-4 conjugated to monomethyl auristatin E.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results